Clearmind Medicine (CMND) announced that on December 10, 2025, the company received a notification letter from Nasdaq stating that, based on the company’s Form 6-K filed on December 5, 2025, it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2.5M. Nasdaq has informed the company that it will continue to monitor the company’s compliance with the Minimum Stockholders’ Equity Rule. If, at the time of the company’s next periodic report, the company does not demonstrate compliance with this requirement, the company may be subject to delisting.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Atai Beckley granted U.S. patent for EMP-01
- Psychedelic: Clearmind reports CMND-100 dosing at Hadassah Medical Center
- Clearmind advances CMND-100 to dosing phase at Hadassah Medical Center
- Clearmind Medicine announces milestones in Phase I/IIa trial for CMND-100
- Clearmind Medicine files to sell 5.78M common shares for holders